Efficacy News and Research

RSS
Repros receives US patent for Androxal

Repros receives US patent for Androxal

Molecular imaging helps physicians determine patient suitability for ICD therapy

Molecular imaging helps physicians determine patient suitability for ICD therapy

OptiNose's bi-directional nasal device delivering fluticasone effective in reducing nasal polyps in CRS patients

OptiNose's bi-directional nasal device delivering fluticasone effective in reducing nasal polyps in CRS patients

Silence Therapeutics receives patent for RNA silencing method

Silence Therapeutics receives patent for RNA silencing method

Entelos receives patent for PhysioLab virtual patient technology

Entelos receives patent for PhysioLab virtual patient technology

OptiMedica to sell retina and glaucoma assets to Topcon

OptiMedica to sell retina and glaucoma assets to Topcon

Two NJIT biomedical researchers receive Coulter Foundation Translational Awards for patent application

Two NJIT biomedical researchers receive Coulter Foundation Translational Awards for patent application

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Cardiovascular Systems fourth-quarter revenue increases 15% to $18.0 million

Cardiovascular Systems fourth-quarter revenue increases 15% to $18.0 million

Study suggests zinc supplementation may reduce pneumonia risk

Study suggests zinc supplementation may reduce pneumonia risk

CADTH Review Panel releases recommendations for Biologic Response Modifier Agents for Adults with RA

CADTH Review Panel releases recommendations for Biologic Response Modifier Agents for Adults with RA

Arrowhead Research signs option agreement for new technology platform to kill fat tissue

Arrowhead Research signs option agreement for new technology platform to kill fat tissue

Amarin provides progress update on MARINE and ANCHOR trials for treating elevated triglyceride levels

Amarin provides progress update on MARINE and ANCHOR trials for treating elevated triglyceride levels

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Pharmasset third-quarter net loss increases to $16.0 million

Pharmasset third-quarter net loss increases to $16.0 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.